Tracon commences dosing in Phase III trial of TRC105 to treat angiosarcoma



US-based clinical-stage biopharmaceutical firm Tracon Pharmaceuticals has commenced dosing in its Phase III trial of TRC105 in combination with Votrient (pazopanib) for the treatment of angiosarcoma.

Related Links:

AbstractThe classification of vascular neoplasms continues to evolve as we accumulate more genetic and clinical data, particularly for rare tumor types. Because of tumor rarity, changes to classification schema, overlapping histologic features, and in some cases, lack of morphologic evidence of vasoformation, vascular neoplasms present a diagnostic challenge. Here, we discuss recent developments in our understanding of vascular tumors, with a detailed discussion of epithelioid hemangioma, tufted angioma, kaposiform hemangioendothelioma, composite hemangioendothelioma, pseudomyogenic hemangioendothelioma, epithelioid hemang…

Source: Virchows ArchivCategory: Pathology Source Type: research

Here, we report a case of pyothorax ‐associated angiosarcoma. Our patient had computed tomography (CT) scans of the chest annually to monitor chronic empyema, and to screen for cancers. Our patient was diagnosed with angiosarcoma within a month period after complaining of chest pain. This is the very first report on angiosarcoma who se aggressive growth could be observed on CT imaging. An 82 ‐year‐old man with chronic tuberculous empyema visited our hospital for an annual computed tomography (CT) scan. No differences were noted between the CT scan at presentation and a scan performed a year previously in August 2017….

Source: Respirology Case ReportsCategory: Respiratory Medicine Authors: Tags: Case Report Source Type: research

Vinyl chloride (VC) is a common industrial organochlorine, shown to cause hepatic angiosarcoma and hepatic steatosis. However, the role of endoplasmic reticulum stress (ERS) and oxidative stress (OS) in hepatic steatosis after subchronic exposure to VC in mice, is unclear. Based on body weight, forty healthy SPF male C57BL/6 J mice were randomly divided into a control group and three VC exposure groups (57.3, 286.7, and 1433.6 ppm) (n = 10 each). VC was administered by static inhalation in a 50 L sealed plexiglass inhalation chamber for 2 h per day, five days per week for 16 weeks. Serum and…

Source: Toxicology and Applied PharmacologyCategory: Toxicology Authors: Tags: Toxicol Appl Pharmacol Source Type: research

We present a case of an undifferentiated subtype of non-keratinizing squamous cell carcinoma (NK-SCC) with sarcomatoid features in the nasopharynx in a 69-year-old man who was difficult to diagnose due to spindle-shaped malignant cells. He was admitted because of a right nasal obstruction and right headache, and imaging revealed a heterogeneously enhanced irregularly shaped mass at the nasopharynx. Histopathologically, the tumour was partially organised, and the tumour cells were epithelioid or spindle-shaped. Initially, we erroneously diagnosed the tumour as an angiosarcoma owing to its false-negative immunoreaction for c…

We report our experience of combined chemo- and radiotherapy in the clinical course of 6 patients with cutaneous angiosarcoma who were treated between 2007 and 2018.
RESULTS: All patients presented non-resectable tumours and were treated with radiotherapy in combination with the administration of liposomal, pegylated doxrubicin (25 mg/m2 every 2 weeks). The mean duration of progression-free survival was 8 months (5-14 months), corresponding to an overall survival of 13 months (13-34 months). A partial response was seen in 4 patients and 1 patient developed progressive dise…

Introduction: Cutaneous angiosarcoma (CAS) is a rare, malignant tumor of vascular mesenchymal origin accounting for

AbstractBackgroundPrimary cardiac angiosarcoma (PCAS) is a rare type of tumour. Furthermore, descriptions of the demographic features and prognostic factors of PCAS patients have been poorly reported.MethodsA population cohort study was conducted using retrospectively extracted data from the SEER (Surveillance, Epidemiology and End Results) database for patients with histological diagnoses of PCAS; the extracted information included demographic, treatment and outcome data.ResultsA total of 168 cases of PCAS from 1973 to 2013 were included. The mean age at diagnosis was 44.4  ± 15.5 years. PCAS was…

Within the context of the presented case, the patient likely developed radiation-associated angiosarcoma (RAA).1 The timeframe fits because most cases of RAA occur between 2 to 12  years postradiation. Additionally, the clinical features are consistent with RAA, which usually develops in the dermis of the radiated skin. In contrast, primary angiosarcoma more commonly develops in the breast parenchyma.2 We counsel patients who present for postoperative radiation to the breast that the risk of developing radiation-induced malignancy in the treatment field is about 1 in 1000 to 1 in 10,000 over 10 years.

Angiosarcoma (AS) develops in various soft tissues and organs, but the most frequently affected site is the skin, commonly occurring in the scalp of elderly people and typically presenting as an enlarging bruise-like purpura [1 –5]. In the most of patients, AS is relatively large at the time of diagnosis because of a significant delay in diagnosis. There are some treatment options, however, an effective treatment has not been established yet, resulting in the poor prognosis.

Source: Journal of Dermatological ScienceCategory: Dermatology Authors: Source Type: research


Source link